Contents

Search

IDH2 gene mutation (RealTime IDH2 Assay)

Indications: - refractory acute myeloid leukemia (AML) - mutations in IDH2 gene confer eligibility for enasidenib (Idhifa) - evaluation of gliomas (CPT) - eligibility for vorasidenib (FDA-approval pending)

Related

NADP isocitrate dehydrogenase 2 (isocitrate dehydrogenase [NADP] mitochondrial)

General

gene mutation testing; gene mutation analysis

References

  1. FDA News Release. August 1, 2017 FDA approves new targeted treatment for relapsed or refractory acute myeloid leukemia. https://www.fda.gov/newsevents/newsroom/pressannouncements/ucm569421.htm